share_log

ShockWave Medical (NASDAQ:SWAV) Shares Down 6.7% After Insider Selling

ShockWave Medical (NASDAQ:SWAV) Shares Down 6.7% After Insider Selling

冲击波医疗(纳斯达克:SWAV)内部人士抛售后股价下跌6.7%
Financial News Live ·  2022/09/22 11:52

ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating)'s share price was down 6.7% on Thursday after an insider sold shares in the company. The stock traded as low as $264.56 and last traded at $265.72. Approximately 6,539 shares traded hands during trading, a decline of 99% from the average daily volume of 485,127 shares. The stock had previously closed at $284.69.

在一名内部人士抛售Shockwave Medical,Inc.股票后,该公司股价周四下挫6.7%。该股盘中一度跌至264.56美元,最新报265.72美元。全天约有6,539股股票易手,较485,127股的日均成交量下降99%。该股此前收盘报284.69美元。

Specifically, VP Trinh Phung sold 3,500 shares of ShockWave Medical stock in a transaction on Friday, August 26th. The shares were sold at an average price of $310.76, for a total value of $1,087,660.00. Following the sale, the vice president now owns 25,063 shares of the company's stock, valued at approximately $7,788,577.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ShockWave Medical news, CFO Dan Puckett sold 1,100 shares of ShockWave Medical stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $291.33, for a total transaction of $320,463.00. Following the sale, the chief financial officer now owns 39,938 shares of the company's stock, valued at approximately $11,635,137.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Trinh Phung sold 3,500 shares of ShockWave Medical stock in a transaction on Friday, August 26th. The stock was sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the sale, the vice president now directly owns 25,063 shares in the company, valued at approximately $7,788,577.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,700 shares of company stock valued at $30,247,696. 3.90% of the stock is owned by company insiders.

具体地说,副总裁Trin h Phung在8月26日(星期五)的一次交易中出售了3500股Shockwave Medical股票。这些股票的平均价格为310.76美元,总价值为1,087,660.00美元。出售股份后,总裁副手现在持有该公司25,063股股票,价值约7,788,577.88美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。在其他Shockwave Medical的消息中,首席财务官Dan Puckett在9月20日星期二的一笔交易中出售了1100股Shockwave Medical的股票。这些股票以291.33美元的平均价格出售,总成交金额为320,463.00美元。出售后,首席财务官现在拥有该公司39,938股股票,价值约11,635,137.54美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在美国证券交易委员会网站。此外,副总裁Trin h Phung在8月26日(星期五)的一笔交易中出售了3500股Shockwave Medical股票。股票以310.76美元的平均价格出售,总成交金额为1,087,660.00美元。出售股份后,总裁副手现在直接持有该公司25,063股股份,价值约7,788,577.88美元。关于这次销售的披露可以找到这里。在上个季度,内部人士出售了108,700股公司股票,价值30,247,696美元。3.90%的股份由公司内部人士持有。

Get
到达
ShockWave Medical
冲击波医疗
alerts:
警报:

Analysts Set New Price Targets

分析师设定新的价格目标

Several research firms have recently commented on SWAV. Morgan Stanley lifted their price target on ShockWave Medical from $201.00 to $255.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 9th. Wells Fargo & Company boosted their price objective on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a report on Tuesday, August 9th. Piper Sandler boosted their price objective on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an "overweight" rating in a report on Monday, August 29th. Canaccord Genuity Group boosted their price objective on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a "buy" rating in a report on Tuesday, August 9th. Finally, Oppenheimer lowered shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective on the stock. in a report on Tuesday, September 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $246.50.

几家研究公司最近对SWAV发表了评论。摩根士丹利在8月9日周二的一份报告中将Shockwave Medical的目标价从201.00美元上调至255.00美元,并给予该股“同等权重”的评级。富国银行将Shockwave Medical的股票目标价从176.00美元上调至255.00美元,并在8月9日周二的一份报告中给予该公司“增持”评级。在8月29日周一的一份报告中,派珀·桑德勒将Shockwave Medical的股价目标从278.00美元上调至338.00美元,并给予该公司“增持”评级。在8月9日周二的一份报告中,Cancord Genuity Group将Shockwave Medical的股票目标价从232.00美元上调至256.00美元,并给予该公司“买入”评级。最后,奥本海默将Shockwave Medical的股票评级从“市场表现”下调至“表现不佳”,并为该股设定了165.00美元的目标价。在9月6日星期二的一份报告中。一位研究分析师对该股的评级为卖出,一位分析师给出了持有评级,七位分析师给出了该公司的买入评级。根据MarketBeat.com的数据,该公司目前的普遍评级为“适度买入”,平均目标价为246.50美元。

ShockWave Medical Price Performance

冲击波医疗价格表现

The company has a debt-to-equity ratio of 0.02, a current ratio of 5.32 and a quick ratio of 4.41. The company has a market capitalization of $9.47 billion, a PE ratio of 183.17 and a beta of 1.06. The stock's 50 day simple moving average is $262.48 and its 200-day simple moving average is $207.86.
该公司的负债权益比为0.02,流动比率为5.32,速动比率为4.41。该公司市值为94.7亿美元,市盈率为183.17,贝塔系数为1.06.该股的50日简单移动均线切入位在262.48美元,200日简单移动均线切入位在207.86美元。

ShockWave Medical (NASDAQ:SWAV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.25. ShockWave Medical had a return on equity of 21.25% and a net margin of 15.11%. The business had revenue of $120.70 million during the quarter, compared to the consensus estimate of $107.51 million. During the same period in the previous year, the company posted ($0.01) earnings per share. The business's revenue for the quarter was up 115.5% on a year-over-year basis. As a group, equities analysts forecast that ShockWave Medical, Inc. will post 2.57 earnings per share for the current fiscal year.

冲击波医疗(纳斯达克:SWAV-GET评级)上一次公布季度收益数据是在8月8日(星期一)。该公司公布本季度每股收益为0.68美元,比分析师普遍预期的0.43美元高出0.25美元。Shockwave Medical的股本回报率为21.25%,净利润率为15.11%。该业务本季度的收入为1.207亿美元,而普遍预期为1.0751亿美元。去年同期,该公司公布的每股收益为0.01美元。该业务本季度的收入同比增长了115.5%。作为一个整体,股票分析师预测ShockWave Medical,Inc.本财年每股收益将达到2.57美元。

Hedge Funds Weigh In On ShockWave Medical

对冲基金参与ShockWave Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. grew its position in shares of ShockWave Medical by 104.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 166 shares of the company's stock worth $29,000 after buying an additional 85 shares in the last quarter. CWM LLC boosted its holdings in ShockWave Medical by 219.7% in the second quarter. CWM LLC now owns 195 shares of the company's stock valued at $37,000 after purchasing an additional 134 shares in the last quarter. AdvisorShares Investments LLC acquired a new position in ShockWave Medical in the first quarter valued at approximately $40,000. PenderFund Capital Management Ltd. acquired a new position in ShockWave Medical in the first quarter valued at approximately $41,000. Finally, First Horizon Advisors Inc. boosted its holdings in ShockWave Medical by 3,666.7% in the second quarter. First Horizon Advisors Inc. now owns 226 shares of the company's stock valued at $43,000 after purchasing an additional 220 shares in the last quarter. 95.40% of the stock is owned by institutional investors and hedge funds.

机构投资者和对冲基金最近改变了他们在该股的头寸。第四季度,洛克菲勒资本管理公司持有的冲击波医疗股份增加了104.9%。洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)在上个季度又购买了85股,现在持有166股该公司股票,价值2.9万美元。Cwm LLC在第二季度增持了Shockwave Medical的股份219.7%。Cwm LLC现在持有195股该公司股票,价值3.7万美元,上个季度又购买了134股。AdvisorShares Investments LLC在第一季度收购了ShockWave Medical的一个新头寸,价值约为4万美元。PenderFund资本管理有限公司在第一季度收购了Shockwave Medical的一个新头寸,价值约为41,000美元。最后,First Horizon Advisors Inc.在第二季度增持了3,666.7%的Shockwave Medical股份。First Horizon Advisors Inc.现在持有226股该公司股票,价值43,000美元,该公司在上个季度又购买了220股。95.40%的股票由机构投资者和对冲基金持有。

About ShockWave Medical

关于冲击波医疗

(Get Rating)

(获取评级)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical,Inc.是一家医疗设备公司,致力于开发和商业化血管内碎石技术,用于治疗全球外周血管、冠状动脉和心脏瓣膜疾病患者的钙化斑块。该公司提供用于治疗膝关节以上外周动脉疾病(PAD)的M5导管;用于治疗冠状动脉疾病的C2导管;以及用于治疗膝盖以下PAD的S4导管。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Is The Golden Age Of Homebuilding Already Over?
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免费获取StockNews.com关于Shockwave Medical(SWAV)的研究报告
  • 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
  • 这些机构持有达顿餐饮国际公司的股份
  • 这三大股利支付者也拥有强劲的价格增长
  • 住房建设的黄金时代已经结束了吗?
  • 天然气价格继续回升,这些股票应该会受益

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《冲击波医学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ShockWave Medical和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发